Welcome to our dedicated page for SOCIETAL CDMO news (Ticker: SCTL), a resource for investors and traders seeking the latest updates and insights on SOCIETAL CDMO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SOCIETAL CDMO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SOCIETAL CDMO's position in the market.
Societal CDMO (NASDAQ: SCTL) will release its financial results for Q1 2022 on May 11, 2022, after market close. The company specializes in complex formulation and manufacturing challenges in small molecule therapeutics. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and operational highlights. Interested parties can access the call via phone or through the company’s website. An archived version will be available for 30 days post-event.
Societal CDMO (SCTL) has secured a task order agreement exceeding $400,000 from the National Cancer Institute’s DCTD for the manufacture and packaging of ammonium tetrathiomolibdate (ATTM) capsules. This project will involve developing a scalable process for cGMP production of 100 mg ATTM capsules, including an engineering batch and a larger cGMP batch with a 36-month stability study. ATTM is believed to enhance the effectiveness of platinum-based antitumor agents. CEO David Enloe emphasized the company's commitment to supporting cancer research through this collaboration.
Societal CDMO (NASDAQ: SCTL) has announced the hiring of new employees to fill various roles, along with the approval of inducement stock option grants totaling 107,540 shares. These options, granted under NASDAQ's inducement grant exception, have an exercise price aligned with the stock closing price on March 31, 2022, and will vest over four years. The company specializes in contract development and manufacturing, focusing on small molecules, and operates state-of-the-art facilities in Gainesville, GA, and San Diego, CA.